Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines
Abstract Background Breast cancer is the leading malignancy among Filipino women, with about 23.50% of cases characterized by human epidermal growth factor receptor-2 (HER2) overexpression. Trastuzumab, in addition to standard chemotherapy, is currently recommended as primary treatment for HER2-posi...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2019-11-01
|
| Serie: | BMC Health Services Research |
| Soggetti: | |
| Accesso online: | http://link.springer.com/article/10.1186/s12913-019-4715-8 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|